Florida / New York | ADVERTISE

A Publication for the Practising Medical Specialist, Industry Executive & Investor

Alithea Genomics Launches MERCURIUS™ Total DRUG-seq: A Next-Generation Full-Length Transcriptome Profiling Platform for High-Throughput Compound Screening and Target Validation

“MERCURIUS™ Total DRUG-seq represents a new frontier in transcriptome-scale compound screening,” said Riccardo Dainese, CEO and Co-founder of Alithea Genomics. “We are empowering scientists to capture the full complexity of transcriptional responses—at a massive scale and with minimal cost. This product opens the door to discovering new biology, new targets, and new drugs faster than ever before.”

Alithea Genomics, a pioneering biotech company based in Switzerland and the USA specializing in scalable RNA sequencing solutions, today announced the launch of MERCURIUS™ Total DRUG-seq, a new extraction-free, full-length transcriptome profiling library preparation kit designed to push the boundaries of high-throughput drug screens, toxicology screens and target validation by enabling the creation of large-scale data generation for machine learning and AI.

Building on the success of its MERCURIUS™ 3’ DRUG-seq, MERCURIUS™ Total DRUG-seq captures the complete transcriptome—including lncRNAs and other non-coding RNAs—with greater sensitivity, full-length coverage, and unprecedented multiplexing capacity, enabling researchers to screen over 50,000 samples with confidence.

The kit is available in 96-well (1,000–25,000 cells) and 384-well (500–10,000 cells) formats and features a streamlined, extraction-free protocol that delivers faster turnaround, lower input requirements, and expanded insights, without sacrificing scalability or reproducibility.

“MERCURIUS™ Total DRUG-seq represents a new frontier in transcriptome-scale compound screening,” said Riccardo Dainese, CEO and Co-founder of Alithea Genomics. “We are empowering scientists to capture the full complexity of transcriptional responses—at a massive scale and with minimal cost. This product opens the door to discovering new biology, new targets, and new drugs faster than ever before.”

MERCURIUS™ Total DRUG-seq is now available for ordering as a standalone kit or as part of Alithea’s in-house services.

Attendees of Discovery and Development Europe (June 2025) are invited to visit Alithea Genomics at booth 64 to explore the new MERCURIUS™ Total DRUG-seq solution alongside other products in the MERCURIUS™ DRUG-seq product line.

About RNA Sequencing

RNA sequencing (RNA-seq) examines the quantity and sequences of RNA molecules in a biological sample using next-generation sequencing (NGS). By revealing which genes are expressed and to what extent, RNA-seq provides a high-resolution view of cellular function. These insights are essential across the drug discovery pipeline, from biomarker discovery to therapeutic development.

Other Device News

Sleep Apnea

Sleep Apnea Threatens Women’s Cognitive Health | Ignored and Undiagnosed

Alzheimer’s disease affects more than 6 million Americans, and emerging research identifies Obstructive Sleep Apnea (OSA) as a significant, modifiable risk factor. Interrupted breathing during sleep can impair memory and accelerate cognitive decline, with growing evidence linking poor sleep to an increased risk of dementia. In response, Vivos Therapeutics is offering innovative, airway-centered treatments aimed at improving sleep quality and supporting long-term brain health.